Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study
Journal of Infection and Public Health · 2025
DOI: 10.1016/j.jiph.2025.102735 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Infection and Public Health, 2025. Verfasst von Tsung-Ying Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory and Regenerative Medicine, MacKay Medical College, New Taipei City, Taiwan; Research Institute for Science and Engin…. Hauptthemen laut MEDLINE: Ceftazidime, Anti-Bacterial Agents, Azabicyclo Compounds, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc, Kaohsiung Medical University.
Abstract (Originalsprache)
OBJECTIVES: Ceftazidime-avibactam (CAZ-AVI) has been launched in Asian countries for five years, but local real-world data about patient characteristics, efficacy, and safety of CAZ-AVI is limited. We conducted a multicenter, retrospective study to investigate the clinical characteristics, microbiology, and outcomes of patients treated with CAZ-AVI for Gram-negative bacterial infection in Taiwan. METHODS: This investigation was conducted as a multicenter retrospective cohort study involving five medical centers in Taiwan. Adult patients with documented/suspected Gram-negative bacterial infection and received ≥ 24 hours of CAZ-AVI were eligible for study cohort enrollment. In-hospital mortality was defined as the primary outcome, while symptom resolution or significant improvement, considered the secondary outcome, was defined as clinical success. RESULTS: Among the 472 patients treated by CAZ-AVI, 46.2 % (218/472) had respiratory tract infections, 22.0 % (104/472) had complicated urinary tract infections, 14.0 % (66/472) had complicated intra-abdominal infections, and 10.0 % (47/472) had primary bacteremia. Most patients receiving ceftazidime/avibactam in Taiwan are old (mean: 70.6 years old), have a high SOFA score (mean 8.4), and have a high Charlson Comorbidity Index score (345/472, 73.1 % ≥ 4). 90 % of CAZ-AVI were used as targeted therapy for pathogens, including Klebsiella pneumoniae (64.4 %, 304/472), Pseudomonas aeruginosa (17.8 %, 84/472), Escherichia coli (8.3 %, 39/472), and Enterobacter spp. (2.3 %, 11/472). The overall clinical success rate is 58.1 % (274/472). The in-hospital mortality rate is 41.1 % (194/472). CONCLUSIONS: Most patients receiving CAZ-AVI as targeted therapy in Taiwan with characteristics of older age, high SOFA scores, and high CCI scores. Receiving immunomodulators, higher SOFA score, and Enterobacter spp. infections were the significant factors associated with in-hospital mortality, whereas early initiating CAZ-AVI treatment and CAZ-AVI monotherapy are associated with better outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory and Regenerative Medicine, MacKay Medical College, New Taipei City, Taiwan; Research Institute for Science and Engineering, Waseda University, Japan; Department of Medical Laboratory Sci…
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Tai…
- Division of Infectious Diseases, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; Ph.D. Program in…
- Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Förderung
- Pfizer Inc
- Kaohsiung Medical University
Zitieren
APA
Yang, T. Y., Huang, C. T., Liu, P. Y., Lin, Y. T., Huang, Y. S., Chang, P. H., Tseng, C. H., Chang, Y. T., Lu, P. L., & Chen, Y. C. (2025). Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2025.102735
Vancouver
Yang TY, Huang CT, Liu PY, Lin YT, Huang YS, Chang PH, et al. Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study. Journal of Infection and Public Health. 2025. doi:10.1016/j.jiph.2025.102735
BibTeX
@article{Yang2025,
author = {Yang, Tsung-Ying and Huang, Ching-Tai and Liu, Po-Yu and Lin, Yi-Tsung and Huang, Yu-Shan and Chang, Peng-Hao and Tseng, Chien-Hao and Chang, Ya-Ting and Lu, Po-Liang and Chen, Yee-Chun},
title = {Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study},
journal = {Journal of Infection and Public Health},
year = {2025},
doi = {10.1016/j.jiph.2025.102735}
}
EUVIMED